Drug
Olaratumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | Anti-PDGFRα mAb |
| Mechanism of Action | Anti-PDGFRα antibody |
| Half-life | ~11 d (range 6–24 d) |
Location
Treated site
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No radiosensitization demonstrated (reduced microvessel density without tumor growth-delay benefit), though evidence is very limited (Song et al., EBioMedicine, 2019).
Data on this page refer exclusively to patients treated with
Olaratumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-PDGFRα mAb group page.